Physician profile
Mohammed Hadi
NPI 1275760100
$10,421.56
in general payments reported to CMS, 2019-2025
49 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 78% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,403 · 2020: $486 · 2021: $1,455 · 2022: $1,157 · 2023: $1,996 · 2024: $1,627 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321 · Travel and Lodging: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,320.67 |
| Travel and Lodging | $600.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,973.74 | 2021-2025 | |
| Abbott Laboratories | $1,767.71 | 2019-2023 | Proclaim, Axium |
| Medtronic, INC. | $766.69 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Pacira Pharmaceuticals Incorporated | $649.21 | 2023-2024 | Iovera, Exparel |
| Collegium Pharmaceutical, INC. | $393.13 | 2022-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $389.15 | 2019-2025 | Ztlido, Elyxyb |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.73 | 2019-2025 | Relistor |
| Boston Scientific Corporation | $291.97 | 2019-2022 | |
| Nevro Corp. | $290.38 | 2021-2024 | Senza |
| Allergan, INC. | $279.86 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $246.23 | 2023-2025 | Horizant, Horizant |
| Bioventus LLC | $229.43 | 2022-2025 | Supartz Fx Sodium Hyaluronate, Supartz Fx Sodium Hyaluronate, Gelsyn-3 |
| Medtronic USA, INC. | $201.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.13 | 2020-2025 | Jardiance |
| Valinor Pharma, LLC | $189.48 | 2023-2025 | Movantik |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Hadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.